Parkinson's disease: prospects for prevention and improved therapy
Mera, S.L.
British Journal of Biomedical Science 53(3): 177-178
1996
ISSN/ISBN: 0967-4845 PMID: 8914340 Document Number: 457402
Document emailed within 1 workday
Related Documents
2002: Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved MMW Fortschritte der Medizin Suppl. 2: 88Jankovic, J. 2001: Parkinson's disease therapy: treatment of early and late disease Chinese Medical Journal 114(3): 227-234
Burgasov, P.N. 1982: Achievements and prospects of infectious disease prevention Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 1982(12): 3-7
Williams, A.; Waring, R. 1993: The MPTP tale: pathway to prevention of Parkinson's disease? British Journal of Hospital Medicine 49(10): 716-719
Jiménez Jiménez, F.J.; Ladero Quesada, J.M. 1990: An experimental model of Parkinson disease caused by a neurotoxin: implications in the clinical aspects and the etiology of Parkinson disease Medicina Clinica 94(15): 585-595
Balabolkin, M.I. 1987: Diabetes mellitus: prospects for therapy and the prevention of late complications Terapevticheskii Arkhiv 59(11): 3-8
Tanasanvimon, S.; Ayuthaya, N.I.N.; Phanthumchinda, K. 2007: Modified Parkinson's Disease Sleep Scale (MPDSS) in Thai Parkinson's disease patients Journal of the Medical Association of Thailand 90(11): 2277-2283
Hattori, N. 2004: Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease Rinsho Shinkeigaku 44(4-5): 241-262
Roth, J.; Růzicka, E.; Kanovský, P. 2000: Advance in therapy Parkinson's disease Vnitrni Lekarstvi 46(11): 811-816
Livshyts', L.A.; Gryshko, V.I.; Kravchenko, S.A. 1992: Possibilities and prospects of the use of DNA analysis in the diagnosis and prevention of inherited disease in the Ukraine Tsitologiia i Genetika 26(4): 35-42
Beliaev, I.K.; Kazarian, R.V.; Zaraĭskiĭ, A.V. 1992: Prospects of the use of beta-carotene enriched food products in the prevention and therapy of radiation injuries Voprosy Pitaniia 1992(2): 58-61
Bhat, V.; Weiner, W.J. 2005: Parkinson's disease. Diagnosis and the initiation of therapy Minerva Medica 96(3): 145-154
Wicklmayr, M.; Rett, K.; Standl, E. 1994: How can primary prevention of coronary heart disease be improved in general practice? Medizinische Klinik 89(4): 184-6 229
Clowes, A.W. 1991: Prevention and management of recurrent disease after arterial reconstruction: new prospects for pharmacological control Thrombosis and Haemostasis 66(1): 62-66
Muenter, M.D.; Sharpless, N.S.; Tyce, G.M. 1972: Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease Mayo Clinic Proceedings 47(6): 389-395
Horisberger, J.D. 2000: Placebo surgery in trials of therapy for Parkinson's disease New England Journal of Medicine 342(5): 354-355
Slattery, J. 2000: Placebo surgery in trials of therapy for Parkinson's disease New England Journal of Medicine 342(5): 354; Author Reply 355
Pacchetti, C.; Aglieri, R.; Mancini, F.; Martignoni, E.; Nappi, G. 1998: Active music therapy and Parkinson's disease: methods Functional Neurology 13(1): 57-67
Danielczyk, W. 1995: Twenty-five years of amantadine therapy in Parkinson's disease Journal of Neural Transmission. Supplementum 46: 399-405
Pfeiffer, C.; Wagner, M.L. 1994: Clozapine therapy for Parkinson's disease and other movement disorders American Journal of Hospital Pharmacy 51(24): 3047-3053